
Browsing restrictions can be lifted for a fee.
Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, brain health series, body regulation series, throat moistening series, hair care series, clear eye series, colorful lifestyle series, joint health series, nutritional supplement series, energy supplement series, immune modulation series, low burden series, sleep aid series, body curve series, circulation series, man power series, women's intimate health series, and mature woman series. In addition, the company offers customization, ODM, dosage, and application services. Greenyn Biotechnology Co., Ltd was founded in 2012 and is based in Taichung, Taiwan.
6846
綠茵
-1.41%
(-0.01)
The most recent financial report for 綠茵 (6846) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6846's short-term business performance and financial health. For the latest updates on 6846's earnings releases, visit this page regularly.
According to historical valuation range analysis, 綠茵 (6846)'s current price-to-earnings (P/E) ratio is 11.32, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 綠茵 (6846) reported an Operating Profit of 35.72M with an Operating Margin of 17.38% this period, representing a decline of 6.13% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 綠茵 (6846) announced revenue of 205.49M, with a Year-Over-Year growth rate of -2.05%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 綠茵 (6846) held Total Cash and Cash Equivalents of 771.71M, accounting for 0.38 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 綠茵 (6846) achieved the “three margins increasing” benchmark, with a gross margin of 48.81%%, operating margin of 17.38%%, and net margin of 14.64%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6846's profit trajectory and future growth potential.
According to the past four quarterly reports, 綠茵 (6846)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
綠茵 (6846)'s Free Cash Flow (FCF) for the period is -167.51M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1,324.25% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.